Cardiovascular
Evans JM, Cleves A, Morgan H, Millar L, Carolan-Rees G. ENDURALIFE-powered cardiac resynchronisation therapy defibrillator devices for treating heart failure: a NICE Medical Technology Guidance. Appl Health Econ Health Policy. 2018 Apr;16(2):177-86. doi: 10.1007/s40258-017-0354-6.
Gilsenan A, Fortuny J, Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Harding A, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu E, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study. Drug Saf. 2019 Oct;42(10):1179-90. doi: 10.1007/s40264-019-00835-0
INTRODUCTION: The serotonin 5-HT4 receptor agonist prucalopride is approved in the European Union for the treatment of chronic constipation. This offered the unique opportunity to include real-world observational data on cardiovascular safety in the new drug application for approval of prucalopride in the USA.
Quin J, Nangia A, Tarola C, Serrano M, Gabany J, Sapirstein J, O’Donnell CJ, Haime M, Zenati M. Surgical bioprosthetic aortic valve replacement: discharge anticoagulation practices and one-year survival. Poster presented at the Association of VA Surgeons 41st Annual Surgical Symposium; May 9, 2017. Houston, TX.
Abstract not available at this time.
Ogunsola T, Serraro M, Nangia A, Phillips A, MacCallum G, Aragam J, Quin J, Zenati M. Aortic valve replacements: eight year trend at a single institution. Poster presented at the Association of VA Surgeons 41st Annual Surgical Symposium; May 9, 2017. Houston, TX.
Abstract not available at this time.
Bhatt M, Ghio M, Nangia A, Sadri L, Plauche L, Dechert T. Understanding the broken heart: risk factors and outcomes for Takotsubo's cardiomyopathy in critically injured trauma patients. Poster presented at the 76th Annual Meeting of the American Association for the Surgery of Trauma and Clinical Congress of Acute Care Surgery; September 2017. Baltimore, MD.
Mody FV, Goyal RK, Ajmera M, Cainzos-Achirica M, Davis KL, Lindstrom RC, Globe G, Riebman JB, Wirtz HS, Amin A. Exploring the association between heart rate control and patient outcomes: a retrospective medical record review of patients hospitalized with systolic heart failure. Poster presented at the 2019 Heart Failure Society of America 23rd Annual Scientific Meeting; September 14, 2019. Philadelphia, PA. [abstract] J Card Fail. 2019 Aug; 25(8 Supplement):S156. doi: 10.1016/j.cardfail.2019.07.447
Lewis EF, Coles TM, Lewis S, Nelson LM, Barrett A, DeMuro Romano C, Stull DE, Turner SJ, Chang CG. Development, psychometric evaluation, and initial feasibility assessment of a symptom tracker for use by patients with heart failure (HFaST). J Patient Rep Outcomes. 2019 May 2;3(1):26. doi: 10.1186/s41687-019-0113-6
Gilsenan A, Fortuny J, Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Harding A, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu I, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cardiovascular safety of prucalopride for chronic constipation: a multinational population-based cohort study. Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):33. doi: 10.1002/pds.4864
BACKGROUND: The serotonin 5-HT4 receptor agonist prucalopride is approved in the European Union (EU) for the treatment of chronic constipation, thus providing opportunity to include real-world observational data on cardiovascular safety to support approval of prucalopride in the United States.
Fortuny J, Gilsenan AW, Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort in a multinational study: study design and comparability of cohorts. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):627. doi: 10.1002/pds.4864
BACKGROUND: Given prior safety experience with other 5-HT4 agonists, an observational cohort study was conducted to evaluate the cardiovascular (CV) safety of prucalopride in support of approval of prucalopride for chronic constipation (CC) in the United States.